Skip to main content

Table 3 Genes associated with primary neuropathological pathways

From: Mice defective in interferon signaling help distinguish between primary and secondary pathological pathways in a mouse model of neuronal forms of Gaucher disease

Gene WT + CBE versus WT + PBS WT + CBE versus
MyTrMaSt + PBS
CBE + SRT
  Fold-change Fold-change  
SL metabolism
Ugt8a − 3.46 − 3.97 ++
Fa2h − 2.00 − 2.00 ++
Gal3st1 − 2.42 − 1.33 n.s.
Cholesterol metabolism
Msmo1 − 2.28 − 2.27 ++
Ch25h 20.3 12.8 +
Dhcr7 − 2.78 − 1.62 n.s.
Tm7sf2 − 2.05 − 1.44 n.s.
Hmgcs1 − 2.63 − 2.07 n.s.
Fdps − 2.90 − 2.10 n.s.
Lipoprotein metabolism and lipid droplets
Apoc1 2.76 2.42 ++
Plin21 5.57 2.90 ++
Plin4 9.97 41.3 ++
Apoe 1.85 1.56 +
Metalloproteinases
Adam8 6.20 5.20 +
Mt11 3.80 3.40 ++
Mt2 6.30 4.80 ++
Lysosome
Gusb1 6.08 5.88 n.s.
Hexb 3.43 3.17 +
Naglu 2.60 2.27 +
CtsD1 4.48 4.68 +
Ctsz 6.62 5.30 +
Galns 2.88 2.39 n.s.
Neuronal genes
Ccdc160 − 2.33 − 2.11 n.s.
Glra1 − 2.04 − 2.63 n.s.
Srpk1 − 2.45 − 2.05 n.s.
Inflammation (chemokines)
Ccl3 39.7 55.5 +
Ccl4 49.2 32.7 +
Cx3cr11 3.70 2.10 n.s.
Inflammation (TNF)
Tnfrsf1a 3.02 4.68 +
Tnfaip8l2 4.08 4.02 +
Slamf9 16.1 15.0 +
Ltbr 2.33 3.08 n.s.
Litaf 3.32 2.32 n.s.
Inflammation (TGF)
Tgfbr2 2.02 2.81 n.s.
Cd109 8.53 10.4 ++
Inflammation (IL6)
Il6ra 5.03 3.08 n.s.
Osmr 4.73 9.70 +
Inflammation (Microglia)
Lyz2 13.2 7.80 +
Mpeg1 9.07 11.5 +
Cd68 8.08 13.9 +
Inflammation (Astrocytes)
Agt 2.10 2.80 n.s.
Gfap 9.86 9.69 +
Complement
C1qa 4.16 4.61 +
C1qb 5.55 5.11 +
C1qc 7.53 5.17 +
C4b 7.35 7.08 +
C5ar11 27. 7 14.8 +
DAMs
Trem2 6.12 8.88 +
Tyrobp1 6.65 6.55 +
Cd63 3.70 3.20 +
Clec7a 43.9 31.3 +
Csf1 3.14 2.20 -
Itgax 61.1 39.6 -
Others
St14 3.28 4.85 -
Mrpl35 − 2.33 − 2.03 n.s.
  1. Genes whose levels were changed < 2-fold in MyTrMaSt mice compared with WT mice. Fold-changes were all statistically significant (p < 0.01). The right-hand column indicates genes that reverted to control levels upon SRT (from Blumenreich et al., submitted for publication; see Discussion).
  2. n.s. not significant
  3. 1 Validated by PCR: WT + CBE versus WT + PBS, fold-change 7.9 ± 3.1 (Plin2), 1.8 ± 0.2 (Mt1), 5.9 ± 1.4 (Gusb), 5.9 ± 1.4 (CtsD), 3.1 ± 0.6 (Cx3cr1), 31.4 ± 3.8 (C5ar1), 11.4 ± 3.0 (Tyrobp). MyTrMaSt + CBE versus MyTrMaSt + PBS, fold-change 4.1 ± 1.3 (Plin2), 1.9 ± 0.2 (Mt1), 6.7 ± 0.5 (Gusb), 5.2 ± 0.5 (CtsD), 3.2 ± 0.4 (Cx3cr1), 15.9 ± 1.2 (C5ar1), 9.1 ± 0.5 (Tyrobp)
  4. + Genes whose expression were reduced upon SRT, yet remained upregulated
  5. ++ Genes that reverted to control levels upon SRT
  6. - Genes whose expression was not affected upon SRT